An estimate of the cost of administering intravenous biological agents in Spanish day hospitals
Joan Miquel Nolla,1 Esperanza Martín,2 Pilar Llamas,3 Javier Manero,4 Arturo Rodríguez de la Serna,5 Manuel Francisco Fernández-Miera,6 Mercedes Rodríguez,6 José Manuel López,7 Alexandra Ivanova,8 Belén Aragón9...
Main Authors: | Nolla JM, Martín E, Llamas P, Manero J, Rodríguez de la Serna A, Fernández-Miera MF, Rodríguez M, López JM, Ivanova A, Aragón B |
---|---|
Format: | Article |
Language: | English |
Published: |
Dove Medical Press
2017-03-01
|
Series: | Therapeutics and Clinical Risk Management |
Subjects: | |
Online Access: | https://www.dovepress.com/an-estimate-of-the-cost-of-administering-intravenous-biological-agents-peer-reviewed-article-TCRM |
Similar Items
-
Effectiveness and safety of intravenous golimumab with and without concomitant methotrexate in patients with rheumatoid arthritis in the prospective, noninterventional AWARE study
by: Aaron Broadwell, et al.
Published: (2023-03-01) -
Prevalence of adverse reactions to intravenously administered originator biologics in patients with rheumatoid arthritis: A 5-year retrospective study
by: Haya M. Almalag, et al.
Published: (2022-07-01) -
Comparative study of the adverse effects of subcutaneous and intraveneous infusion in patients admitted to neurology ward
by: Simin Jahani, et al.
Published: (2009-10-01) -
Subcutaneously-Administered Infliximab in the Management of Rheumatoid Arthritis: A Short Narrative Review of Current Clinical Evidence
by: Iannone F, et al.
Published: (2022-06-01) -
Patient-reported outcome assessment of inflammatory arthritis patient experience with intravenously administered biologic therapy
by: Gaylis NB, et al.
Published: (2017-09-01)